# TransMEM Gas Exchange -- Project 1, Aim 2

> **NCT01925729** · PHASE1 · COMPLETED · sponsor: **Cuneyt M. Alper** · enrollment: 84 (actual)

## Conditions studied

- Middle Ear Disease
- Nasal Allergy

## Interventions

- **BIOLOGICAL:** ragweed
- **BIOLOGICAL:** histamine
- **DRUG:** pseudoephedrine
- **DRUG:** Oxymetazoline

## Key facts

- **NCT ID:** NCT01925729
- **Lead sponsor:** Cuneyt M. Alper
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-01
- **Primary completion:** 2019-03-22
- **Final completion:** 2019-03-22
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2020-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01925729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01925729, "TransMEM Gas Exchange -- Project 1, Aim 2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01925729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*